Port Vila, Republic of Vanuatu — March 4, 2026 — Australasian Medical Research is pleased to announce the publication of an important new review article in the Journal of Clinical Oncology & Advanced Therapy (Volume 2, Issue 1):
“Rethinking Tissue Preservation in Skin Cancer Treatment: Surgical Margins versus Molecular Selectivity”, authored by B.E. Cham, Ph.D. (DOI: 10.63721/26JCOAT0116).
The article examines evolving paradigms in the treatment of non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), with a focus on tissue preservation and molecular precision in clinical care.
“For decades, Mohs micrographic surgery has been regarded as the gold standard for treating many forms of NMSC, offering high cure rates and meticulous histologic margin control,” the author states. However, the review argues that emerging molecular-selective therapies merit equal consideration as standards of care due to their potential to eliminate malignant cells while sparing healthy tissue.
Comparing Surgical and Molecular Approaches
The review contrasts two fundamentally different therapeutic strategies:
- Mohs micrographic surgery, a highly effective excisional technique that removes the tumour with surrounding tissue and often requires reconstructive procedures in cosmetically sensitive areas.
- Molecular-selective therapy, exemplified by Curaderm, a topical treatment containing solasodine rhamnoside glycoalkaloid complex BEC, which selectively induces apoptosis in cancer cells via binding to mutant rhamnose-binding receptors.
Clinical and histological studies — including long-term follow-ups — indicate that treatments based on solasodine glycosides can achieve durable lesion clearance with scarless healing and preservation of normal tissue architecture, offering profound advantages in functional and cosmetic outcomes over surgical excision.
Shifting the Definition of “Complete Clearance”
The article argues that traditional definitions of “complete cancer removal,” which focus primarily on physical excision margins, should evolve in the era of precision oncology. Molecular-targeted, non-surgical therapies like Curaderm provide comparable oncologic efficacy while minimizing disruption to surrounding healthy tissue and improving quality of life for patients.
B.E. Cham, Ph.D., corresponding author and senior researcher at Australasian Medical Research, stated:
“Advances in molecular and cellular oncology now invite clinicians to think beyond physical excision. As precision medicine progresses, therapeutic goals should encompass not only cure rates but also tissue preservation and cosmetic outcomes.”
The open-access review article is available now for researchers, clinicians, and healthcare professionals worldwide.